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Abstract. Metastasis is the main cause of death for cancer 
patients. Targeting factors that control metastasis formation is 
a major challenge for clinicians. Lysophosphatidic acid (LPA) 
is a bioactive phospholipid involved in cancer. LPA activates 
at least six independent G protein-coupled receptors (LPA1-6). 
Tumor cells frequently co-express multiple LPA receptors, 
puzzling the contribution of each one to cancer progression. 
All three receptors, LPA1, LPA2 and LPA3, act as oncogenes 
and prometastatic factors in the mouse mammary gland. The 
competitive inhibitor of LPA1 and LPA3 receptors, Ki16425, 
inhibits efficiently breast cancer bone metastases in animal 
models. We showed here that Debio 0719, which corresponds 
to the R-stereoisomer of Ki16425 exhibited highest antagonist 
activities at LPA1 (IC50=60 nM) and LPA3 (IC50=660 nM) than 
Ki16425 [IC50=130 nM (LPA1); IC50=2.3 µM (LPA3)]. In vitro, 
Debio 0719, inhibited LPA-dependent invasion of the 4T1 mouse 
mammary cancer cells. In vivo, early but not late administration 
of Debio 0719 (50 mg/kg p.o. twice daily) to BALB/c mice during 
the course of orthotopic 4T1 primary tumor growth reduced 
the number of spontaneously disseminated tumor cells to bone 
and lungs without affecting the growth of primary tumors and 
tumor-induced angiogenesis. We found that increased LPA1 
mRNA expression in primary tumors of breast cancer patients FRUUHODWHGVLJQLÀFDQWO\ZLWKWKHLUSRVLWLYHO\PSKQRGHVWDWXV
(p<0.001). Altogether, our results suggest that LPA1 controls 
early events of metastasis independently of cell proliferation and 
angiogenesis. Therefore, targeting this receptor with Debio 0719 
has a high therapeutic potential against metastasis formation for 
breast cancer patients.
Introduction
Lysophosphatidic acid (LPA) is a natural bioactive phospho-
lipid with growth factor-like activities (1). LPA controls cell 
proliferation, motility and differentiation on many cell types 
including cancer cells due to the action of cell surface G 
protein-coupled receptors. At least six LPA receptors have been 
described as transducers of LPA activity (LPA1-6) (2). These 
six LPA receptors can be further subdivided into two groups, 
the EDG family of LPA receptors (including LPA1-3) and the 
purinergic family (including LPA4-6). LPA receptors are widely 
expressed in tissues. Among these receptors LPA1 has the most 
ubiquitous spectrum of expression in the organism (3). LPA is 
implicated in several physiological and pathological processes 
(immunological system, fertility, central nervous system, renal ÀEURVLVOXQJÀEURVLVKDLUORVVFDQFHU7KHPRUHLPSRUWDQW
source of LPA in the organism comes from platelet activity upon 
platelet aggregation (5). LPA can also be produced by cells, 
including tumor cells that express the nucleotide-pyrophosphate 
pyrophosphatase 2/autotaxin/ATX (6,7). Accumulating data 
over the past ten years indicate that LPA is involved in cancer 
progression (8). LPA might be involved in carcinogenesis since 
a series of studies reported that mRNA expression for LPA2 
and LPA3 were elevated in numerous cancers (9-12). Recently, 
overexpression of each EDG family LPA receptor (LPA1, LPA2 
and LPA3) in the mammary gland of MMTV-LPAr transgenic 
mice was shown to induce tumor formation and metastasis 
(13). We have shown that LPA-derived from platelets controls 
bone metastasis formation of breast cancer cells (14). Since its 
discovery as an autocrine motility factor produced by mela-
noma cells, ATX was shown to control the metastatic behavior 
of breast cancer cells (13,15). These data indicate that at least 
in the mammary gland LPA receptors might act as oncogenic 
drivers and that through the activation of these receptors, LPA 
might act as a pro-metastatic factor.
LPA1 mRNA was consistently found expressed in human 
primary breast tumors (11,14). We have shown previously 
that the LPA1 expressed by breast cancer cells controls bone 
metastasis formation in a mouse model (16). For that reason, 
the treatment of bone metastatic animals with the competitive 
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inhibitor of LPA1 and LPA3 receptors, Ki16425 (17), inhibits HIÀFLHQWO\WKHSURJUHVVLRQRIERQHPHWDVWDVHV+RZHYHU
because of the inoculation route of tumor cells directly into the 
blood stream, the role of LPA1 in spontaneous dissemination of 
breast cancer cells from a primary tumor site is still misunder-VWRRG,QOLJKWRIWKHVHÀQGLQJVZHXQGHUWRRNWKHVWXG\RIWKH
role of LPA1 in the spontaneous dissemination of breast cancer 
cells to lungs and bone taking advantage of: i) the development 
of a new antagonist of LPA1/3 receptors Debio 0719, ii) the use of 
a mouse model exploiting the 4T1 mouse mammary cancer cell 
line which recapitulates the distinct steps of metastasis when 
engrafted into the mammary glands of syngenic BALB/C mice 
(18) and iii) a large collection of mRNA from primary tumors 
of breast cancer patients.
Materials and methods
Drugs and reagents. Lysophosphatidic acid (LPA, Oleoyl C18:1) 
and lysophosphatidylcholine (LPC) were obtained from Avanti 
Polar Lipids. Debio 0719 and Debio 0719-425 (S) which corre-
spond to the R-stereoisomer and S-stereoisomer, respectively, of 
the competitive inhibitor of LPA1 and LPA3 receptors, Ki16425 
(17), were synthesized by Debiopharm S.A.
Cell culture. The 4T1 mouse mammary cancer cell line was 
obtained from the American Type Culture Collection and were 
cultured in complete media, DMEM medium (Invitrogen), 
10% (v/v) fetal bovine serum (FBS, Perbio) and 1% penicillin/VWUHSWRP\FLQ,QYLWURJHQDWÝ&LQD&22 incubator. 4T1 
cells derive from a BALB/c spontaneous mammary carcinoma 
and are naturally resistant to 6-thioguanine (21). For dissemi-
nated 4T1 tumor cell (DTC) analysis, bone marrow cells were KDUYHVWHGIURPWLELDVDQGIHPXUVRIHDFKDQLPDOE\ÁXVKLQJ
Cells were placed on 10-cm culture dishes in presence of 
complete media supplemented with 6-thioguanine 10 µM $OGULFK$IWHUWZRZHHNVUHVLVWDQWFORQHVZHUHÀ[HGVWDLQHG
and counted. The amount of rescued DTC was expressed in 
terms of cell clones/mm2.
Calcium flux assays. Assays were conducted using Chemi-
Screnn Calcium-optimized Chem-1 stable cell line expressing 
human recombinant LPA1 receptor (Milipore Corp., St. Charles, 
MO). To test for LPA1 agonist activity, cells were loaded with )OXR1:DQGFDOFLXPÁX[LQUHVSRQVHWRROHR\O/3$.L
and Debio 0719 were determined in eight point 3-fold serial 
dilution dose starting at 10 µM. EC80 values for the reference 
agonist were determined upon agonist addition in a dose-depen-
dent manner. IC50 values for Ki16425 and Debio 0719 were 
determined by addition of antagonist and incubation of 90 sec, 
followed by ligand stimulation at EC80 concentration.
Patients and tumor characteristics. Studies involving human 
primary breast tumors were performed according to the principles 
embodied in the Declaration of Helsinki. Tissue biopsies were 
obtained as part of surgical treatments for the hormone receptor 
content determination. Remaining samples were included anony-
mously in this study. All human experiments were approved by 
the Experimental Review Board from the Laennec School of 
Medicine that waived the need for consent. The study cohort 
corresponded to 104 pre-menopausal patients treated between 
October 1994 and October 2001 (37). Criteria for inclusion in WKHVWXG\ZHUHDVIROORZSULPDU\EUHDVWWXPRUZLWKRXWLQÁDP-PDWRU\IHDWXUHVQRSUHYLRXVFDQFHUWKHUDS\DQGQRLGHQWLÀHG
metastasis at the time of diagnosis. Estrogen receptor (ER) and 
progesterone receptor (PgR) were assayed in cytosol using the 
radioligand reference method (EORTC, 1980). Results were 
expressed as fmol/mg cytosol protein. ER and PgR positive 
tumors contained >2 and >5 fmol/mg protein, respectively.
RNA extraction. Breast cancer tissue biopsies were obtained by 
surgery, selected by the pathologist and immediately snap-frozen 
in liquid nitrogen until processing. The biopsies were pulverized 
using a Mikro-Dismembrator (B. Braun Biotech International, 
Melsungen, Germany) and total RNAs were extracted using 
TRI Reagent (Sigma, St. Louis, MO). To remove any genomic 
DNA contamination, total RNAs were treated with RNAse-free '1$VH,DQGSXULÀHGXVLQJ51HDV\PLFURFROXPQV4LDJHQ+LOGHQ*HUPDQ\51$TXDOLW\ZDVYHULÀHGXVLQJDQ$JLOHQW
Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA).
Reverse transcription and quantitative real-time polymerase 
chain reaction (RT-QPCR). Expression of LPA1 mRNA was TXDQWLÀHGE\UHDOWLPHTXDQWLWDWLYH573&5RQDQ(SSHQGRUI
Mastercycler® RealPlex (Invitrogen) using the SYBR® Green 3&5NLW)LQQ]\PHV4XDQWLÀFDWLRQVZHUHQRUPDOL]HGWRFRUUH-VSRQGLQJ51$/DQG7%3YDOXHV7KHF'1$VZHUHDPSOLÀHGE\3&5IRUF\FOHVZLWKWKHIROORZLQJVSHFLÀF3&5SULPHUV
human LPA1, 5'-TGGCATTAAAAATTTTACAAAAACA-3' 
(forward) and 5'-AATAGTTAACAACATGGGAATGG-3' 
(reverse); human L32, 5'-CAAGGAGCTGGAAGTGCTGC-3' 
(forward) and 5'-CAGCTCTTTCCACGATGGC-3' (reverse); 
human TBP, 5'-TGGTGTGCACAGGAGCAAG-3' (forward) 
and 5'-TTCACATCACAGCTCCCCAC-3' (reverse). Each cycle FRQVLVWHGRIVHFRIGHQDWXUDWLRQDWÝ&VHFRIDQQHDOLQJDWÝ&IRU/3$1DQGÝ&IRU/DQG7%3IROORZHGE\VHFRIH[WHQVLRQDWÝ&([SHULPHQWDOSURFHGXUHVZHUHIROORZHGDV
described (15).
Cell invasion assay. Invasion assays were carried out using 
Bio-Coat migration chambers (Becton-Dickinson) with 8-µm ÀOWHUVSUHYLRXVO\FRDWHGZLWK0DWULJHODVGHVFULEHGSUHYLRXVO\
(38). 4T1 cells (2x105) were plated in the upper chambers in 
presence of absence of increasing concentrations of Debio 0719 
and LPA in the lower chambers in presence of 1% fetal bovine VHUXP$IWHULQFXEDWLRQIRUKDWÝ&LQ&22 incubator, FHOOVWKDWKDGPLJUDWHGWKURXJKWKHÀOWHUVZHUHÀ[HGDQGVWDLQHG
The membranes were mounted on glass slides, and cells from 10 UDQGRPPLFURVFRSLFÀHOGVPDJQLÀFDWLRQ[ZHUHFRXQWHG$OO
experiments were run in duplicate, and invasion was expressed in 
terms of cells/mm2.
Pharmacokinetic studies. Experiments were performed at 
Shanghai Medicilion Inc. (Shanghai, China) using CD-1 male 
mice. Debio 0719 was administered in a solution of 10% DMA, 
5% Cremophor EL and 85% saline to mice. Debio 0719 was 
administered intravenously at a dose of 5 mg/kg as a 10 ml/
kg bolus into the jugular vein. For oral exposure, Debio 0719 
was administered via an oral gavage at a dose of 50 mg/kg in a 
volume of 20 ml/kg. Blood samples were collected from retro-
orbital puncture in sodium heparin containing tubes (n=3 for 
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each time-point). Plasma samples (100 µl) were transferred to 
Eppendorf tube, then 20 µl methanol and 500 µl internal solution 
(Lovastatin, 500 ng/ml) were added. After vortexing for 1 min 
and centrifuging for 5 min at 15,000 rpm, supernatant was trans-
ferred to new vials and 5 µl of plasma samples were analyzed 
for Debio 0719 concentration by liquid chromatography/mass 
spectrometry. The liquid chromatography was carried out 
using an Agilent liquid chromatograph (Agilent Technologies). 
Mass spectrometric analysis was performed using an API3000 
(triple-quadrupole) instrument from ABI Inc (Concord, Ontorio, 
Canada) with an ESI interface. Data acquisition and control 
system were created using Analyst 1.4 software from ABI Inc.
In vivo oncological studies. The mice used in our study were 
handled according to the rules of Décret no. 87-848 du 
19/10/1987, Paris. The experimental protocol have been 
reviewed and approved by the Institutional Animal Care and 
Use Committee of the Université Claude Bernard Lyon-1 (Lyon, 
France). Studies were routinely inspected by the attending 
veterinarian to ensure continued compliance with the proposed 
protocols. BALB/C mice, 4 weeks of age, were housed under EDUULHUFRQGLWLRQVLQODPLQDUÁRZLVRODWHGKRRGV$XWRFODYHG
water and mouse chow were provided ad libitum. Animals 
bearing tumor xenografts were carefully monitored for estab-
lished signs of distress and discomfort and were humanely HXWKDQL]HGZKHQWKHVHZHUHFRQÀUPHG7XPRUIDGSDGH[SHUL-
ments were performed using 4T1 cells (105 in 10 µl of PBS) 
injected into the fat pad of the 4th mammary gland of female 
BALB/c mice of 6 weeks of age (Charles River). Animals were 
treated per os with Debio 0719 (25 mg/kg twice daily or 50 mg/
kg twice daily) from day 0 to 14 or from day 15 to 35 post tumor 
cell injection. Primary tumors were resected 14 days after tumor 
cell injection and tumor weights were measured. For sponta-
neous metastasis dissemination studies, 14 days after tumor cell 
injection, animals were anesthetized and primary tumors were 
surgically removed. Mice were then followed for an additional ZHHNREVHUYDWLRQDWZKLFKWLPHWKH\ZHUHVDFULÀFHGOXQJV
were collected for histological analysis and bone marrow cells ZHUHKDUYHVWHGIRU'7&TXDQWLÀFDWLRQ
Immunohistochemistry. 5HVHFWHGSULPDU\WXPRUVZHUHÀ[HGDQGHPEHGGHGLQSDUDIÀQ)LYHPVHFWLRQVZHUHVXEMHFWHG
to immunohistochemistry. Detection of the nuclear antigen 
Ki-67 was carried out as described previously (15). The Ki-67 
mitotic index was calculated as the ratio of the number of Ki-67 SRVLWLYHQXFOHLWRWKHWRWDOQXFOHXVQXPEHUSHUÀHOGDQGUHVXOWV
were expressed as the percentage of Ki-67-positive nuclei. For 
microvessel detection, immunostaining was performed with 
a rabbit polyclonal antibody against von Willebrand factor 
(vWF), and a rat monoclonal antibody against mouse CD31 
(PECAM-1). Tumor angiogenesis was evaluated using the 
Chalkley's Grid. Data were expressed as the percentage of marks RQWKHJULGWKDWFRYHUVWDLQHGYHVVHOVIURPLQGHSHQGHQWÀHOGV
on each tumor tissue section.
Statistical analysis. Data were analyzed with the StatView 5.0 
software using unpaired Student's t-test for in vitro and in vivo 
studies. Analysis of the distribution of LPA1 expression in rela-
tion to usual prognostic parameters was performed with the 
non-parametric Mann-Whitney test or Kruskall-Wallis test.
Results
Debio 0719 inhibits LPA/LPA1VWLPXODWHGFDOFLXPÁX[ZLWKD
stronger potency than Ki16425. Since its discovery, the competi-
tive inhibitor Ki16425 was extensively used to address the role 
of LPA1 both in vitro and in vivo (16,17,19,20). To evaluate the 
role of LPA1LQPHWDVWDVLVZHÀUVWFKDUDFWHUL]HGWKHSKDUPDFR
dynamic properties of two derivatives of Ki16425, Debio 0719 
and Debio 0719-425(S). Debio 0719 and Debio 0719-425(S) 
correspond to the R-stereoisomer and S-stereoisomer, respec-
tively, of the Ki16425, which is a racemic mixture of R- and 
S-stereoisomers, in a ratio of ~50:50. Debio 0719 and Debio 
0719-425(S) were tested for agonist activity by incubating 
increasing concentrations of Debio 0719 and Debio 0719-425(S) 
(0.0045-10 µM) with Chem-1 cells expressing human LPA1 and PHDVXULQJFDOFLXPÁX[)LJ$/LNH.L'HELR
and Debio 0719-425(S) showed no agonist activity at the 
LPA1 receptor at any concentration tested, whereas increasing 
concentrations of oleoyl LPA showed dose-dependent stimula-WLRQRIFDOFLXPÁX[ZLWKDQDYHUDJH(&50 of 490 nM. Debio LQKLELWHG/3$LQGXFHGFDOFLXPÁX[LQ/3$1-expressing 
)LJXUH&DOFLXPÁX[DVVD\$$VVHVVPHQWRI'HELRPHGLDWHGDJR-
nism of the LPA1 receptor. Human LPA1-expressing Chem-1 stable cell line 
was incubated with increasing concentrations of Oleoyl LPA, Ki16425, Debio 
0719 or Debio 0719-425(S) (0.0045-10 µM) and then assayed for stimulation of FDOFLXPÁX[%'RVHGHSHQGHQWDQWDJRQLVPRI/3$LQGXFHGFDOFLXPÁX[WR
human LPA1-expressing Chem-1 stable cell line was incubated with increasing 
concentrations of Ki16425, Debio 0719 or Debio 0719-425(S) (0.0045-10 µM) 
in the presence of 1 µM Oleoyl LPA. 
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Chem-1 cells in a dose-dependent manner, resulting in IC50 value 
of 60 nM (Fig. 1B). Parallel experiments showed that Ki16425 
inhibited LPA-induced LPA1GHSHQGHQWFDOFLXPÁX[LQ&KHP
cells with a higher IC50 value of 130 nM and Debio 0719-425(S) 
with much higher IC50 value of 2.8 µM. Based on these results, 
Debio 0719 revealed 2-fold more potent than Ki16425 at 
inhibiting LPA1FHOOVLJQDOLQJWKDWFRQWUROFDOFLXPÁX[7KXVWKH
R-stereoisomer can be considered as the active stereoisomer of 
Ki16425 to inhibit LPA/LPA1LQGXFHGFDOFLXPÁX[7KHUHIRUH
all subsequent experiments presented here were carried out by 
using only Debio 0719.
Debio 0719 inhibits 4T1 breast cancer cell invasion in response 
to LPA. Recent studies have shown that LPA1 is the main receptor 
that transduces the cell migratory activity of LPA (19). The 
4T1 mouse mammary cancer cells mimic the successive steps 
of growth and metastasis of breast cancers observed in clinic 
when injected in the mammary fat-pad of immunocompetent 
BALB/c mice (18,21). These cells express all subtypes of LPA 
receptors including LPA1 (15). We found previously that 4T1 
cells respond to LPA as a chemo-attractant in a cell invasion 
assay (15). We observed here that the migratory activity of LPA 
was dose-dependently blocked on cells treated with increasing 
concentrations of Debio 0719 (Fig. 2).
Pharmacokinetics. The therapeutic potential of a pharmaco-
logical compound is linked to its stability and bioavailability 
in vivo. Therefore, we next measured the plasma concentration 
time curves for Debio 0719 in male CD-1 mice after both 
intravenous and oral administration (Fig. 3). After oral dosing 
(50 mg/kg), Debio 0719 concentration peaked at 15 min with a 
Cmax of 3.5 µM thereafter decreasing to ~10 nM by 8 h, yealding 
a t1/2 of 0.98 h. After intravenous dosing (5 mg/kg) a Cmax of 
5.6 µM was observed within 5 min, which decreased to ~1 nM 
by 4 h, yealding a t1/2 of 0.49 h. The oral exposure was high 
with an oral bioavailability 14.41. The detailed pharmacokinetic 
parameters for Debio 0719 are shown in Table I.
Targeting LPA1 in vivo with Debio 0719 does not inhibit primary 
tumor growth of 4T1 cells. To analyze the role of LPA1 during 
the early steps of the metastatic dissemination of breast cancer 
cells, mice were inoculated orthotopically with 4T1 cells in the 
mammary gland and treated with Debio 0719 (25 and 50 mg/
kg) administered orally per os twice daily, or with the vehicle 
only, from day 0 to 14 post cell injection. Treatments were 
stopped at day 14 at which time primary tumors were resected. 
We observed that a daily treatment of animals with Debio 0719 
was well tolerated as judged by a constant gain of weight of the 
mice treated with Debio 0719 (25 and 50 mg/kg) twice daily as 
compared with mice treated with the vehicle (Fig. 4). Second, by 
measuring the weight of resected tumors, we found no differ-
ence in the burden of primary tumors between animals treated 
and not treated with Debio 0719 (Fig. 5A and B). This result 
was rather surprising based on our previous results showing a 
LPA1-dependent mitogenic activity of LPA on human MDA-B02 
breast cancer cells in vitro and in vivo (14). By performing 
immunohistochemical analyses on 4T1 primary tumor sections, 
we found that the expression of the mitotic marker Ki-67 in the 
tumors was similar in animals treated or not treated with Debio 
0719 (Fig. 5C and D). This result indicated that the treatment of 
mice with Debio 0719 had no effect on 4T1 cell proliferation 
in vivo at the site of implantation.
Figure 2. Debio 0719 inhibits LPA-induced 4T1 cell invasion by Debio 0719. 
Cell invasion was stimulated with LPA (5 µM) used as chemoattractant in 
presence of Debio 0719 (1 and 5 µM) placed in the upper chamber. Results 
are the mean ± SD of cells of 3 replicates and are representative of at least 
3 independent experiments. Data are expressed as the number of cells/mm2. 
)LJXUH3KDUPDFRNLQHWLFSURÀOHRI'HELRin vivo. Debio 0719 plasma 
concentration curves for male CD-1 mice after a single oral (PO; 50 mg/kg) 
or intravenous (i.v., 5 mg/kg) administration of Debio 0719.
Table I. Pharmacokinetic parameters for Debio 0719 in male 
CD-1 mice.
Dose route Intravenous (n=3) Oral (n=3)
Dose (mg/kg) 5 50
Plasma clearance (l/h/kg) 6.66 
T1/2 (h) 0.49 0.98
Bioavailability (% EF)  14.41
Cmax (µg/ml) 2960 1658
Time to maximum 0.08 0.25
concentration (h)
All values represent the mean for each parameter.
INTERNATIONAL JOURNAL OF ONCOLOGY  40:  1133-1141,  2012 1137
Targeting LPA1 in vivo with Debio 0719 inhibits spontaneous 
metastasis of 4T1 cells to the lungs. After primary tumor resec-
tions, animals treated with Debio 0719 from day 0 to 14 post 
cell injection were kept for an additional 21-day period and UHFHLYHGQRWUHDWPHQWXQWLOWKHGD\RIVDFULÀFHZKHUHOXQJV
were collected and the number and the area of metastatic foci ZHUHTXDQWLÀHGE\KLVWRORJLFDODQDO\VLV:HREVHUYHGWKDWWKHQXPEHURIOXQJPHWDVWDVLVIRFLZDVVLJQLÀFDQWO\UHGXFHGLQKLEL-
tion = 62%, p=0.022) in animals treated with the higher dosing 
regimen of Debio 0719 compared to the untreated animals or 
to the group of mice receiving the lower dosing of Debio 0719 
(Fig. 6A and B). Treatment of mice with the higher dosing of 'HELRPJNJWZLFHGDLO\DOVRGHFUHDVHGVLJQLÀFDQWO\
the total area of lung metastases (inhibition = 89%, p=0.029) 
compared to untreated animals (Fig. 6C). Animals receiving the 
lower dosing of Debio 0719 presented also a reduction in the 
area of lung metastasis foci but the value did not reach statistical VLJQLÀFDQFHS )LJ&
Targeting LPA1 in vivo with Debio 0719 inhibits dissemination 
of 4T1 cells (4T1-DTCs) to bone. We then asked whether the 
effect of Debio 0719 was restricted to the homing of 4T1 cells 
to the lungs or if its activity impaired the overall metastatic 
process. To address this question we analyzed the presence of 
4T1-disseminated tumor cells (DTCs) at the bone site, as bone 
is one key target tissue of breast cancer derived metastases (22). $WWKHWLPHRIVDFULÀFHERQHPDUURZFHOOVZHUHKDUYHVWHGDQG
4T1-DTCs were rescued in vitro due to their endogenous resis-
tance to the cytotoxic action of 6-thioguanine (21). At that day, 
we were not able to rescue any 4T1-DTCs from animals treated 
with either high or low dose of Debio 0719 (Fig. 6D).
We then asked whether this observation could be due to an 
unexpected side effect of the compound on tumor cell survival LQWKHERQHPDUURZ:HÀUVWO\JHQHUDWHG7WXPRUVLQWKH
mammary fat pad of BALB/c mice and then submitted the 
animals to the treatment with Debio 0719 in an adjuvant setting. 
Primary tumors were resected at day 14 and animals were 
Figure 4. Effect of Debio 0719 treatment on the weight of 4T1-tumor bearing 
animals treated twice daily with Debio 0719 (25 and 50 mg/kg). Syngenic 
female Balb/C mice were inoculated with 4T1 cells by orthotopic injection into 
the mammary fat pad. Treatment with indicated doses of Debio 0719 started 
at day 0 and ended at day 15 post cell injection. Mouse weight was check at 
days 1, 7, 14, and 35. Arrow indicated the time of primary tumor resections.
Figure 5. Effect of Debio 0719 treatment of female Balb/C mice on 4T1 primary tumor growth. 4T1 cells were injected in the mammary gland of normal syngenic 
female BALB/C mice. (A and B) Animals were treated per os twice daily with indicated doses of Debio 0719 from day 0 to 14. At day 14, primary tumors (A) \HOORZFLUFOHVZHUHUHVHFWHGDQGZHLJKHG%UHVXOWVDUHH[SUHVVHGLQPJDVWKHPHDQ6'3ULPDU\WXPRUVZHUHHPEHGGHGLQSDUDIÀQ&DQG'7XPRUWLVVXHVHFWLRQVZHUHDQDO\VHGE\LPPXQRKLVWRFKHPLVWU\XVLQJDVSHFLÀFDQWLERG\GLUHFWHGDJDLQVWWKHQXFOHDU.LDQWLJHQ'7KHPLWRWLFLQGH[ZDVFDOFXODWHGDVWKH
percentage of nuclei positive for Ki-67. Results are the mean ± SD. Scale bar, 150 µm.
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randomized based on the size of resected tumors (Fig. 7A). Then, 
animals were treated or not with Debio 0719 (25 or 50 mg/kg) 
twice daily per osIRUDGD\SHULRG$WWKHWLPHRIVDFULÀFHZHIRXQGQRVWDWLVWLFDOO\VLJQLÀFDQWGLIIHUHQFHLQWKHQXPEHURI
4T1-DTCs rescued from the bone marrow of animals treated 
with Debio 0719 compared to animals treated with the vehicle 
(Fig. 7B). These results indicated that the activity of Debio 0719 
did not impair the survival of cancer cells already present in the 
bone marrow when the treatment was started. Altogether, the 
results suggested that the anti-metastatic activity of Debio 0719 ZDVQRWUHVWULFWHGWRDVSHFLÀFRUJDQEXWLQVWHDGDIIHFWHGWKH
overall metastatic capacity of 4T1 cells.
Targeting LPA1 in vivo with Debio 0719 inhibits spontaneous 
metastasis of 4T1 cells independently of tumor angiogenesis. 
Angiogenesis is well known to control tumor growth and metas-
tasis, and the LPA-LPA1WUDFNPLJKWSOD\DVLJQLÀFDQWUROHLQ
this process (23,24). By quantifying the levels of immunohisto-
chemical endothelial cell markers (vWF and CD31) on 4T1 
primary tumor sections, we found a similar level of angiogenesis 
in tumors collected from animals treated and untreated with 
Debio 0719 (Fig. 8). This result indicated that Debio 0719 did not VLJQLÀFDQWO\LQWHUIHUHZLWKDQJLRJHQHVLVLQWKH7PDPPDU\
tumor model.
High LPA1 expression at the primary tumor site links with posi-
tive lymph node status of pre-menopausal breast cancer patients. ,QFOLQLFO\PSKQRGHVDUHWKHÀUVWVLWHVLQYDGHGE\WXPRUFHOOV
during the metastasis process. Therefore, a high number of posi-
tive lymph nodes contributes to the poor prognosis for patients 
Figure 6. Effect of Debio 0719 treatment of female Balb/C mice on spontaneously metastasis dissemination of 4T1 cells to lungs (A-C) and bone (D). 4T1 cells were 
injected in the mammary gland of normal syngenic female BALB/C mice. Animals were treated per os twice daily with indicated doses of Debio 0719 from day 0 WR$WGD\SULPDU\WXPRUVZHUHUHVHFWHG$QLPDOVZHUHVDFULÀFHGGD\VDIWHUWXPRUFHOOLQMHFWLRQDQGOXQJV$DQGERQHPDUURZFHOOV'ZHUHFROOHFWHGWRTXDQWLI\PHWDVWDVLVVSUHDGLQJRI7FHOOV$/XQJWLVVXHVHFWLRQVVWDLQHGZLWKHRVLQ$UURZVLQGLFDWHGPHWDVWDWLFIRFL6FDOHEDUP4XDQWLÀFDWLRQRI
the number (B) and the area (C) of lung metastasis foci were enumerated under microscope. Data were expressed as total number of foci/lung (B) and total foci 
area (in mm2)/lung (C) (means ± SD). (D) Bone marrow cells were harvested and plated on 10 cm culture dishes, in the presence of 6-thioguanine to rescue only 
4T1-DTCs. 4T1-DTC clones were stained and counted. Data were expressed as the mean of cell density (in mm2) ± SD. Scale bar, 1 cm. 
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with breast cancers (25). We investigated whether LPA1 might 
be linked to lymph node invasion in breast cancer patients. We 
analyzed the expression levels of the mRNA for LPA1 in a series 
of 104 primary tumors from pre-menopausal patients without 
metastasis at the time of diagnosis. Higher LPA1 mRNA expres-VLRQZDVVLJQLÀFDQWO\UHODWHGWRSRVLWLYHQRGHWXPRUVS
(Table II). Any other classical prognostic factors (surgical 
tumor size, histological grade, ER and PgR status) revealed no 
difference (Table II). This suggested that LPA1 expression was 
associated with early steps of metastasis dissemination through 
invasion of lymph nodes of patients with breast cancers.
Discussion
Metastasis is now considered as a very early event during tumor 
growth (26). We found previously that Ki16425, which is a 
competitive inhibitor of LPA1 and LPA3 receptors (17), inhibits HIÀFLHQWO\WKHSURJUHVVLRQRIEUHDVWFDQFHUFHOOPHGLDWHGERQH
metastases in a mouse model (16). Here, we present pharmaco-
kinetic and pharmacodynamic data for Debio 0719, which 
corresponds to the R-stereoisomer of Ki16425. Debio 0719 
was evaluated for its ability to inhibit LPA1 activation by LPA. 
Inhibition of LPA1 activation was measured as a decrease in the /3$VWLPXODWHGFDOFLXPÁX[DV.LZDVGHPRQVWUDWHGWR
block LPA-induced elevation of intracellular calcium (17). The 
average IC50 values for the Debio- and Ki16425-mediated inhibi-
tion of LPA-stimulated human LPA1-expressing Chem-1 stable 
cell line was 60 and 130 nM, respectively, indicating that Debio 
0719 was 2-fold more potent than Ki16425 at inhibiting LPA1-LQGXFHGFDOFLXPÁX[7KLVZDVOLNHO\GXHWRWKHSUHVHQFHRIa
of the S-stereoisomer of Ki16425, which had a poor inhibitory 
activity on LPA/LPA1VWLPXODWHGFDOFLXPÁX[,WLVQRWHZRUWK\
that Debio 0719 did not demonstrate any agonist effects on LPA1 DWFRQFHQWUDWLRQVDVKLJKDV03KDUPDFRNLQHWLFSURÀOH
of Debio 0719 was assessed in male CD-1 mice. Debio 0719 
was well tolerated after oral exposure with a half-life of 0.98 h. 
Administration of Debio 0719 to female Balb/C mice via an oral 
gavage at a dose up to 50 mg/kg twice daily for 14 days, did not 
induce noticeable deleterious effects. We observed that the treat-
Figure 7. Effect of Debio 0719 treatment of female Balb/C mice on dissemi-
nated 4T1 tumor cell survival in bone. 4T1 cells were injected in the mammary 
gland of normal syngenic female BALB/C mice. (A) At day 14, primary tumors 
were resected and animals were randomized according to the tumor size. 
(B) Animals were treated per os twice daily with indicated doses of Debio 0719 IURPGD\WR$QLPDOVZHUHVDFULÀFHGGD\VDIWHUWXPRUFHOOLQMHFWLRQ
and bone marrow cells were collected and plated on 10 cm cell culture dishes, in 
the presence of 6-thioguanine to rescue only 4T1-DTCs. 4T1-DTC clones were 
stained and counted. Data were expressed as the mean of cell density (in mm2) 
± SD. Scale bar, 1 cm.
Figure 8. Effect of Debio 0719 treatment of female Balb/C mice on 4T1 tumor angiogenesis. Primary 4T1 tumors were collected as described in Fig. 5. Tumor WLVVXHVHFWLRQVZHUHDQDO\VHGE\LPPXQRKLVWRFKHPLVWU\XVLQJDVSHFLÀFDQWLERG\GLUHFWHGDJDLQVW&'$DQGY:)%7KHYHVVHOGHQVLW\LQRIWLVVXH
section) was calculated using the Chalkley's Grid. Results are the mean ± SD. Scale bar, 150 µm. 
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ment of mice with Debio 0719 during the early phase of tumor GHYHORSPHQWLQKLELWHGHIÀFLHQWO\WKHIRUPDWLRQRIVSRQWDQHRXV
lung and bone metastases in a preclinical breast cancer mouse 
model exploiting the 4T1 mammary carcinoma cell line. In this 
model, the Debio 0719-mediated reduction in metastasis was 
not related to reduced angiogenesis at the primary tumor site, 
suggesting that LPA1 blockade interferes with another step of 
metastasis formation.
LPA is well known to have a mitogenic activity on a wild 
range of normal and cancer cell types (8). Recent reports demon-
strated that LPA receptors, including LPA1 control directly 
the carcinogenesis through a pro-oncogenic action. By using 
an ErbB2/HER2 inducible system in the non-tumoral human 
MCF-10A breast cell line, Witt and colleagues found that LPA1 
exhibits a fully oncogene activity in proliferation, migration and 
3-dimentional acinar morphogenesis assays (27). However, a 
weak signal from ErbB2/HER2 revealed necessary for LPA1-
induced cell action. An initial transformation step of MEF with 
c-myc and Tbx2 is also required for the oncogenic activity of 
LPA1, LPA2 and LPA4 (28). However, in vivo, individual over-
expression of LPA1, as well as LPA2 and LPA3, driven by the 
MMTV promoter in transgenic mice leads to the formation of 
spontaneous mammary tumors within a year (13). Interestingly, 
over-expression of ATX, an LPA-producing enzyme, in MMTV-
transgenic animals results in a similar spontaneous breast tumor 
formation (13). This work suggested that the sensitization of the 
breast epithelium to LPA, by increasing either the amount of 
cell surface LPA receptors or the local formation of LPA might 
prevail to initiate breast carcinogenesis rather than the control 
of carcinogenesis by a unique subtype of LPA receptor. We 
demonstrated recently that modulating the local production 
of LPA at the primary site of 4T1 breast tumors in animals, 
through stable down-regulation of ATX using an shRNAi 
strategy, decreases spontaneously lung metastasis formation but 
has no impact on primary tumor growth (15). Here, we found 
no effect on the growth of 4T1 mammary tumors in animal 
treated with Debio 0719. These results suggest that targeting 
LPA or its receptor LPA1 in breast cancer patients might most 
likely not lead to successful inhibition of primary tumor growth. 
This hypothesis is supported by the absence of link between the 
size or grade, and the levels of LPA1 expression among breast 
tumors analyzed throughout the present study. It could therefore 
be postulated that clinical trials with compounds targeting LPA 
signaling in breast cancer patients should rely on innovative 
clinical end-points, instead of RECIST criteria. Recently, a 
monoclonal antibody to RANKL (Denosumab) was approved to 
treat bone metastasis based on clinical end-points such as time 
to skeletal related events, rather than standard criteria (29).
LPA receptors share many intracellular signaling path-
ways that control cell behavior (30). LPA is known to induce 
migration and invasion of breast cancer cells through the 
mobilization of LPA receptors and downstream activation 
of the ơ-arrestin/Ral signaling pathway (31,32). Among LPA 
receptors, LPA1ZDVLGHQWLÀHGDVWKHWUDQVGXFHURIWKHPLJUD-
tion activity of LPA on neoplastic and non-neoplastic cells 
(19). However, the idea of having one LPA receptor devoted to 
one function is probably not realistic. Overexpression of LPA 
receptors (LPA1, LPA2, LPA3) individually in the mammary 
gland of MMTV-transgenic mice induces the formation of 
distant metastases in up to 45% of tumor bearing animals (13). 
However, among LPA receptors, LPA1 might play a key role in 
the metastasis process of breast cancers. We found that high 
expression of LPA1 distributed with the nodal status of pre-
menopausal breast cancer patients suggesting that increased 
expression of this receptor might contribute to early steps of 
breast cancer cell metastasis. It was demonstrated, since its 
discovery as a metastasis suppressor gene (33) that Nm23-H1 
down-regulates LPA1 expression in breast cancers (34). LPA1 
re-introduction in breast cancer cells expressing Nm23-H1 ZDVVXIÀFLHQWWRUHVFXHWKHVHFHOOVIURPLQKLELWHGPLJUDWLRQ
and to induce metastasis formation in vivo (35,36).
In conclusion, by using an immunocompetent mouse model, 
based on orthotopic implantation of breast cancer cells, we found 
that blocking LPA1 activity in vivo with Debio 0719 during the HDUO\SKDVHRIWXPRUJURZWKLQKLELWHGHIÀFLHQWO\ERQHDQGOXQJ
Table II. Distribution of LPA1 mRNA expression in different VXEVHWVRIFDVHVGHÀQHGE\WKHXVXDOSURJQRVWLFIDFWRUV
Prognostic factors n Median P-value
Surgical tumor size
 <20 mm 37 5.19 
 PP   
Histological type
 Ductal 89 5.46 
 Lobular 12 5.00   0.793
Histological gradea
 GI 12 5.36 
 GII 43 5.46 
 GIII 29 5.00   0.960
Node status
 Neg 47 3.24 
 Pos 57 6.68 <0.001
ER status
 Neg 27 5.46 
 Pos 77 5.37   0.556
PgR status
 Neg 23 5.55 
 Pos 81 5.25   0.935
ER and/or PgR
 Neg 34 5.56
ER and PgR
 Pos 70 5.04   0.584
a+LVWRORJLFDOJUDGHGHÀQHGRQO\ LQGXFWDOFDUFLQRPD3YDOXHVFRUUH-
spond to Mann-Whitney test or Kruskall Wallis test (histological grade).
INTERNATIONAL JOURNAL OF ONCOLOGY  40:  1133-1141,  2012 1141
metastasis formation. This anti-metastatic effect of Debio 0719 
was mainly due to inhibition of cell invasion but not of cell 
proliferation and angiogenesis. Altogether, our results suggest 
that the level of LPA1 expression at the site of primary tumors 
might control very early events during the metastasis process 
of breast cancers and that targeting LPA1 with Debio 0719 has 
a high therapeutic potential against metastasis formation for 
breast cancer patients.
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